Agranulocytosis associated with etodolac.
OBJECTIVE
To report a case of probable etodolac-induced agranulocytosis.


METHODS
A 72-year-old woman who had been taking etodolac 300 mg bid for approximately six weeks presented to the emergency department with symptoms of urosepsis. She was found to be profoundly granulocytopenic. Etodolac was discontinued and broad-spectrum intravenous antibiotic therapy was administered for the next 17 days. Results of bone marrow biopsy revealed marked hypocellularity consistent with drug-induced agranulocytosis. Following etodolac withdrawal, the total white blood cell count reached a low value of 0.9 x 10(9)/L and then returned to a pre-etodolac baseline after 15 days. Her hemoglobin concentration also decreased significantly during hospitalization.


CONCLUSIONS
Agranulocytosis has rarely been reported in association with nonsteroidal antiinflammatory drugs (NSAIDs), and there are no literature reports associating etodolac with agranulocytosis. This case involving etodolac is consistent with the pattern described with other NSAIDs. Factors correlating etodolac as the causative agent are identified. Details of patient history, treatment, follow-up, and assessment are discussed.


CONCLUSIONS
Detailed case assessment demonstrated probable etodolac-induced agranulocytosis in our patient. Clinicians should be aware that etodolac, like other NSAIDs, has potential to cause agranulocytosis.
Cramer
R L
RL
Department of Pharmacy, Huntsville Hospital, AL 35801.
Aboko-Cole
V C
VC
Gualtieri
R J
RJ
D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced*; D002452:Cell Count; D017308:Etodolac / Q000009:adverse effects*; D005260:Female; D006801:Humans
D017308:Etodolac